ID: ALA497135

Max Phase: Preclinical

Molecular Formula: C27H16N4O6

Molecular Weight: 492.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1cc2c([nH]c3ccccc32)c(-c2ccc3c(n2)C(=O)C(NC(=O)c2ccco2)=CC3=O)n1

Standard InChI:  InChI=1S/C27H16N4O6/c1-36-27(35)19-11-15-13-5-2-3-6-16(13)28-22(15)24(30-19)17-9-8-14-20(32)12-18(25(33)23(14)29-17)31-26(34)21-7-4-10-37-21/h2-12,28H,1H3,(H,31,34)

Standard InChI Key:  XHTANXNLBSPVKV-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.45

Molecular Weight (Monoisotopic): 492.1070

AlogP: 3.85

#Rotatable Bonds: 4

Polar Surface Area: 144.25

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.15

CX Basic pKa: 0.51

CX LogP: 2.75

CX LogD: 2.75

Aromatic Rings: 5

Heavy Atoms: 37

QED Weighted: 0.36

Np Likeness Score: -0.05

References

1. Hassani M, Cai W, Koelsch KH, Holley DC, Rose AS, Olang F, Lineswala JP, Holloway WG, Gerdes JM, Behforouz M, Beall HD..  (2008)  Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies.,  51  (11): [PMID:18457384] [10.1021/jm701066a]

Source

Source(1):

• Scientific Literature